Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: 5HT1A activity than aripiprazole

or Anticonvulsant

or Benzodiazepine

Use the filters below to narrow your results.

None (9) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Dalmane (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Doral (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Halcion (1) · Lexotan (1) · Librium (1) · Luminal (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rexulti (1) · Rohypnol (1) · Sabril (1) · Serax (1) · Tranxene (1) · Versed (1) · Vimpat (1) · Xanax (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

AMPA receptor antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1)

None (40) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (40) · 0.25 mg (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)

None (40) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1)

None (40) · 10 mg/d (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1)

None (40) · Oral (2)

None (40) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)

None (40) · 6 h (immediate-release); ~11 h (extended-release) (1) · Daily dosing (1)

None (40) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~91 hours (1)

None (40) · 80-90% oral (1) · ~95% (1)

None (40) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; National Pregnancy Registry available (1)